BioXcel Therapeutics, Inc. – NASDAQ:BTAI

Add to watchlist

$5.089

+4.69

+1192.33%

Market closed

Open in about 2 hours

-67.44%

month

-67.44%

quarter

-86.60%

year

Market Cap	16.42M
Enterprise value	386.17M

P/E	-3.24
EV/Sales	1029.79
EV/EBITDA	-1.71
Price/Sales	1296.16
Price/Book	6.33
PEG ratio	0.07
EPS	-5.18

Revenue	1.75M
EBITDA	-136.66M
Income	-153.04M
Revenue Q/Q	182.52%
Revenue Y/Y	202.23%

Profit margin	-62639.73%
Oper. margin	-60643.47%
Gross margin	94.67%
EBIT margin	-60643.47%
EBITDA margin	-7782.92%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

BioXcel Therapeutics, Inc. (NASDAQ:BTAI): Profit margin
Jun 2023	457K	-53.51M	-11710.07%
Sep 2023	341K	-50.48M	-14805.28%
Dec 2023	376K	-22.25M	-5919.15%
Mar 2024	582K	-26.79M	-4603.26%

BioXcel Therapeutics Financials Estimate

Q Y

BioXcel Therapeutics, Inc. (NASDAQ:BTAI): Analyst Estimates
Mar 2024	582K	-26.79M	-4603.26%
Sep 2025	3.7M	-11.19M	-302.45%
Oct 2025	3.3M	-11.42M	-346.1%
Dec 2025	4.09M	-9.87M	-240.92%

Analysts Price target
Financials & Ratios estimates

BioXcel Therapeutics, Inc. (NASDAQ:BTAI): Debt to assets
Jun 2023	140097000	134.23M	95.81%
Sep 2023	100449000	141.05M	140.43%
Dec 2023	73702000	130.21M	176.67%
Mar 2024	82323000	154.68M	187.9%

BioXcel Therapeutics, Inc. (NASDAQ:BTAI): Cash Flow
Jun 2023	-38.20M	-20K	250K
Sep 2023	-37.58M	0	0
Dec 2023	-26.86M	0	2.12M
Mar 2024	-17.70M	0	26.62M

BioXcel Therapeutics alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

BioXcel Therapeutics
Employees

BioXcel Therapeutics, Inc. (NASDAQ:BTAI): Employee count
Aug 2023	183
Sep 2023	183
Oct 2023	183
Nov 2023	183
Dec 2023	183
Jan 2024	183
Feb 2024	183
Mar 2024	74
Apr 2024	74
May 2024	74
Jun 2024	74
Jul 2024	74

BioXcel Therapeutics
Hedge Funds Holdings Q1 2023

37.62% -10.36%

of BTAI is owned by hedge funds

64 -17

hedge funds hold BTAI stock

10.53M -2.90M

shares is hold by hedge funds

BTAI hedge funds holdings changes

BioXcel Therapeutics
Insider Trading

BioXcel Therapeutics, Inc. (NASDAQ:BTAI): Insider trades (number of shares)
Period	Buy	Sel
Apr 2024	0	9589
Jun 2024	0	1431252
Sep 2024	0	3391
Oct 2024	0	33041
Dec 2024	0	4289

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Sale	16 Dec 2024	O'NEILL VINCENT officer: See Remarks officer: See Remarks	Common Stock	165	$0.35	$58
Sale	16 Dec 2024	MEHTA VIMAL director, 10 perc..	Common Stock	983	$0.36	$358
Sale	16 Dec 2024	MEHTA VIMAL director, 10 perc..	Common Stock	2,134	$0.36	$773
Sale	16 Dec 2024	STEINHART RICHARD I officer: Chief Financial Officer officer: Chief Financial Officer	Common Stock	205	$0.36	$74
Sale	16 Dec 2024	STEINHART RICHARD I officer: Chief Financial Officer officer: Chief Financial Officer	Common Stock	372	$0.36	$133
Sale	16 Dec 2024	YOCCA FRANK officer: Chief Scientific Officer officer: Chief Scientific Officer	Common Stock	205	$0.36	$73
Sale	16 Dec 2024	YOCCA FRANK officer: Chief Scientific Officer officer: Chief Scientific Officer	Common Stock	225	$0.35	$79
Option	15 Dec 2024	MEHTA VIMAL director, 10 perc..	Common Stock	3,500	N/A	N/A
Option	15 Dec 2024	MEHTA VIMAL director, 10 perc..	Restricted Stock Units	3,500	N/A	N/A
Option	15 Dec 2024	STEINHART RICHARD I officer: Chief Financial Officer officer: Chief Financial Officer	Common Stock	562	N/A	N/A

BTAI insider trading transactions

Status	Patent	Filling date	Issue date
Application	Application TREATMENT OF SARCOMA USING IMMUNOMODULATION Filling date: 17 Feb 2022 Issue date: 18 Aug 2022	17 Feb 2022	18 Aug 2022
Application	Application DEXMEDETOMIDINE TREATMENT REGIMENS Filling date: 4 Jan 2022 Issue date: 21 Jul 2022	4 Jan 2022	21 Jul 2022
Application	Application SYSTEMS AND METHODS OF USING MACHINE LEARNING TO DETECT AND PREDICT EMERGENCE OF AGITATION BASED ON SYMPATHETIC NERVOUS SYSTEM ACTIVITIES Filling date: 18 Mar 2022 Issue date: 30 Jun 2022	18 Mar 2022	30 Jun 2022
Application	Application FILM FORMULATIONS CONTAINING DEXMEDETOMIDINE AND METHODS OF PRODUCING THEM Filling date: 23 Dec 2021 Issue date: 26 May 2022	23 Dec 2021	26 May 2022
Application	Application FILM FORMULATIONS CONTAINING DEXMEDETOMIDINE AND METHODS OF PRODUCING THEM Filling date: 23 Dec 2021 Issue date: 14 Apr 2022	23 Dec 2021	14 Apr 2022
Application	Application NOVEL APPROACH FOR TREATMENT OF CANCER USING IMMUNOMODULATION Filling date: 10 Dec 2019 Issue date: 24 Mar 2022	10 Dec 2019	24 Mar 2022
Application	Application USE OF SUBLINGUAL DEXMEDETOMIDINE FOR THE TREATMENT OF AGITATION Filling date: 7 Oct 2021 Issue date: 3 Feb 2022	7 Oct 2021	3 Feb 2022
Application	Application COMBINATION THERAPIES FOR TREATING DISEASE USING AN INNATE IMMUNITY MODIFIER AND AN OX40 AGONIST Filling date: 10 Dec 2019 Issue date: 27 Jan 2022	10 Dec 2019	27 Jan 2022
Application	Application PREDICTIVE AND DIAGNOSTIC METHODS FOR PROSTATE CANCER Filling date: 9 Jan 2018 Issue date: 18 Nov 2021	9 Jan 2018	18 Nov 2021
Application	Application METHODS FOR TREATING AGITATION USING DEXMEDETOMIDINE HYDROCHLORIDE Filling date: 26 Jun 2019 Issue date: 2 Sep 2021	26 Jun 2019	2 Sep 2021

BioXcel Therapeutics
Earnings Call Transcripts

Quarter	Transcript
Q1 2024 9 May 2024	Q1 2024 Earnings Call Transcript
Q4 2023 12 Mar 2024	Q4 2023 Earnings Call Transcript
Q3 2023 14 Nov 2023	Q3 2023 Earnings Call Transcript
Q2 2023 14 Aug 2023	Q2 2023 Earnings Call Transcript

BTAI earnings call transcripts

BioXcel Therapeutics
Executives

Insider	Age	Since	Compensation
Dr. Vimal D. Mehta Ph.D. (1961) Founder, Chief Executive Officer, Pres, & Director	64		$1,450,000
Dr. Krishnan Nandabalan (1963) Chief Digital Officer ?& Director	62		$150,000

BioXcel Therapeutics
Latest News

Friday, 22 November 2024
08:16	BioXcel Therapeutics Announces Pricing of $7.0 Million Public Offering	globenewswire.com
Thursday, 21 November 2024
16:47	BioXcel Therapeutics Announces Proposed Public Offering	globenewswire.com
Thursday, 14 November 2024
09:20	BioXcel Therapeutics, Inc. (BTAI) Reports Q3 Loss, Lags Revenue Estimates	zacks.com
09:07	BioXcel Therapeutics, Inc. (BTAI) Q3 2024 Earnings Call Transcript	seekingalpha.com
Friday, 8 November 2024
07:00	BioXcel Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024	globenewswire.com
Tuesday, 5 November 2024
11:05	Will BioXcel Therapeutics, Inc. (BTAI) Report Negative Q3 Earnings? What You Should Know	zacks.com
Tuesday, 29 October 2024
07:00	BioXcel Therapeutics to Present at ThinkEquity Conference	globenewswire.com
Tuesday, 15 October 2024
07:00	BioXcel Therapeutics Announces U.S. Department of Defense Grant to University of North Carolina to Fund Study of BXCL501 (Sublingual Dexmedetomidine) for Treating Acute Stress Disorder	globenewswire.com
Thursday, 19 September 2024
07:00	BioXcel Therapeutics Announces Clinical Prioritization and Update on BXCL501 Late-Stage Programs for Agitation	globenewswire.com
Thursday, 5 September 2024
07:00	BioXcel Therapeutics Announces Initiation of SERENITY At-Home Pivotal Phase 3 Safety Trial of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia	globenewswire.com
Friday, 30 August 2024
10:56	BioXcel Therapeutics (BTAI) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now	zacks.com
Friday, 9 August 2024
21:48	BioXcel Therapeutics, Inc. (BTAI) Q2 2024 Earnings Call Transcript	seekingalpha.com
Tuesday, 6 August 2024
09:10	BioXcel Therapeutics, Inc. (BTAI) Reports Q2 Loss, Tops Revenue Estimates	zacks.com
Tuesday, 16 July 2024
07:00	BioXcel Therapeutics Announces Preliminary Estimated Unaudited Second Quarter Net Revenues from Sales of IGALMI™ (dexmedetomidine) Sublingual Film	globenewswire.com
Tuesday, 28 May 2024
07:00	BioXcel Therapeutics to Present at Jefferies Global Healthcare Conference	globenewswire.com
Tuesday, 21 May 2024
07:00	BioXcel Therapeutics Announces Oral and Poster Presentations at the 2024 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting	globenewswire.com
Thursday, 9 May 2024
07:00	BioXcel Therapeutics Reports First Quarter 2024 Financial Results	globenewswire.com
Thursday, 25 April 2024
07:00	BioXcel Therapeutics to Report First Quarter 2024 Financial Results on May 9, 2024	globenewswire.com
Wednesday, 24 April 2024
10:30	BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting	globenewswire.com
Monday, 22 April 2024
07:00	BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market Potential	globenewswire.com
Monday, 15 April 2024
08:29	PRISM MarketView – Biotech Breakfast	prismmediawire.com
Wednesday, 10 April 2024
07:00	BioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal Phase 3 Trial Plan With BXCL501 for Agitation Associated With Alzheimer's Dementia	globenewswire.com
Monday, 25 March 2024
07:00	BioXcel Therapeutics Announces $25 Million Registered Direct Offering	globenewswire.com
Friday, 15 March 2024
07:00	BioXcel Therapeutics Announces European Patent Office's Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual Dexmedetomidine	globenewswire.com
Tuesday, 12 March 2024
11:00	BioXcel Therapeutics, Inc. (BTAI) Q4 2023 Earnings Call Transcript	seekingalpha.com
07:00	BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2023	globenewswire.com
Thursday, 7 March 2024
14:52	7 Short-Squeeze Stocks That Could Send the Bears Into Panic-Mode	InvestorPlace
Friday, 1 March 2024
07:00	BioXcel Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024	GlobeNewsWire
Friday, 9 February 2024
09:05	Why Is BioXcel Therapeutics (BTAI) Stock Down 26% Today?	InvestorPlace
Friday, 24 November 2023
06:40	7 Penny Stocks With Low Floats and High Short Interest	InvestorPlace

Frequently Asked Questions (FAQ)

What's the price of BioXcel Therapeutics stock today?

One share of BioXcel Therapeutics stock can currently be purchased for approximately $5.09.
When is BioXcel Therapeutics's next earnings date?

Unfortunately, BioXcel Therapeutics's (BTAI) next earnings date is currently unknown.
Does BioXcel Therapeutics pay dividends?

No, BioXcel Therapeutics does not pay dividends.
How much money does BioXcel Therapeutics make?

BioXcel Therapeutics has a market capitalization of 16.42M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 268% to 1.38M US dollars.
What is BioXcel Therapeutics's stock symbol?

BioXcel Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "BTAI".
What is BioXcel Therapeutics's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of BioXcel Therapeutics?

Shares of BioXcel Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are BioXcel Therapeutics's key executives?
BioXcel Therapeutics's management team includes the following people:
- Dr. Vimal D. Mehta Ph.D. Founder, Chief Executive Officer, Pres, & Director(age: 64, pay: $1,450,000)
- Dr. Krishnan Nandabalan Chief Digital Officer ?& Director(age: 62, pay: $150,000)
Is BioXcel Therapeutics founder-led company?

Yes, BioXcel Therapeutics is a company led by its founder Dr. Vimal D. Mehta Ph.D..
How many employees does BioXcel Therapeutics have?

As Jul 2024, BioXcel Therapeutics employs 74 workers.
When BioXcel Therapeutics went public?

BioXcel Therapeutics, Inc. is publicly traded company for more then 7 years since IPO on 8 Mar 2018.
What is BioXcel Therapeutics's official website?

The official website for BioXcel Therapeutics is bioxceltherapeutics.com.
Where are BioXcel Therapeutics's headquarters?

BioXcel Therapeutics is headquartered at 555 Long Wharf Drive, New Haven, CT.
How can i contact BioXcel Therapeutics?

BioXcel Therapeutics's mailing address is 555 Long Wharf Drive, New Haven, CT and company can be reached via phone at +47 52 38 68 37.

BioXcel Therapeutics, Inc.

bioxceltherapeutics.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally administered, systemic innate immunity activator for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.

+47 52 38 68 37

555 Long Wharf Drive
New Haven, CT 06511

CIK: 0001720893
ISIN: US09075P1057
CUSIP: 09075P105